Shareholders Reject CEO's Warrant Extension
PBYI has more than doubled off its 52-week low of $3.03.
Summary
Puma Biotechnology shareholders rejected a proposal to extend CEO Alan H. Auerbach's warrant for 2.1 million shares, meaning the warrant will expire as scheduled in October 2026.
Key Events · Corporate Governance and Compliance · PBYI
-
Shareholder Vote Outcome
Shareholders rejected the proposal to extend CEO Alan H. Auerbach's warrant to purchase 2,116,250 shares at $16.00 per share.
-
Warrant Expiration
The warrant will now expire on its original date of October 4, 2026, instead of being extended to October 4, 2028.
-
Corporate Governance
This outcome follows previous proxy filings seeking approval for the extension, indicating a direct shareholder pushback on executive compensation.
Analysis · PBYI · Life Sciences
Shareholders voted against extending CEO Alan H. Auerbach's warrant to purchase 2.1 million shares at $16.00, which was set to expire in October 2026. This rejection, following active solicitation for approval, signals shareholder dissatisfaction with executive compensation or the perceived value of the warrant, preventing a potential future payout for the CEO and avoiding future dilution.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.4% of the 1070 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PBYI was trading at $7.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $364.9M. The 52-week trading range was $3.03 to $7.90. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.